Public's perspective on COVID-19 adenovirus vector vaccines after Thrombosis with thrombocytopenia syndrome (TTS) reports and associated regulatory actions: A Cross-Sectional Study in six EU member states
Research output: Contribution to conference › Poster › Research › peer-review
Standard
Public's perspective on COVID-19 adenovirus vector vaccines after Thrombosis with thrombocytopenia syndrome (TTS) reports and associated regulatory actions : A Cross-Sectional Study in six EU member states. / Buhl, Caroline; Jacobsen, Ramune; Almarsdóttir, Anna Birna; van Vliet, Ella ; Abtahi, Shahab ; Poplavska, Elita ; Ribeiro-Vaz , Inês ; Kos, Mitja ; Čebron Lipovec, Nanča; Dermiki-Gkana, Foteini ; Oikonomou, Chara ; Kontogiorgis, Christos ; Silva , Ana Marta ; Barão Sousa Ferreira, Paula ; Deligianni, Elena; Kursite, Mirdza ; van der Goot, Marloes ; Hegger, Ingrid ; Leonardo Alves, Teresa .
2023. Poster session presented at European Drug Utilization Research Group (EuroDURG) Conference 2023 - Sustainability of drug use: equity and innovation, Bologna, Italy.Research output: Contribution to conference › Poster › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - CONF
T1 - Public's perspective on COVID-19 adenovirus vector vaccines after Thrombosis with thrombocytopenia syndrome (TTS) reports and associated regulatory actions
AU - Buhl, Caroline
AU - Jacobsen, Ramune
AU - Almarsdóttir, Anna Birna
AU - van Vliet, Ella
AU - Abtahi, Shahab
AU - Poplavska, Elita
AU - Ribeiro-Vaz , Inês
AU - Kos, Mitja
AU - Čebron Lipovec, Nanča
AU - Dermiki-Gkana, Foteini
AU - Oikonomou, Chara
AU - Kontogiorgis, Christos
AU - Silva , Ana Marta
AU - Barão Sousa Ferreira, Paula
AU - Deligianni, Elena
AU - Kursite, Mirdza
AU - van der Goot, Marloes
AU - Hegger, Ingrid
AU - Leonardo Alves, Teresa
PY - 2023
Y1 - 2023
N2 - Objective: In 2021, thrombocytopenia syndrome (TTS) was confirmed by the European Medicines Agency (EMA) as a rare side effect of the COVID-19 adenovirus vector vaccines from AstraZeneca or Janssen. This study aimed to describe the public’s knowledge of TTS and how it affected the willingness to be vaccinated with COVID-19 and other vaccines.Methods: In 2022, a multi-country cross-sectional online survey was conducted in Denmark, Greece, Latvia, Netherlands, Portugal and Slovenia. The minimum target of participants to be recruited was linked to the country’s population. The results were analysed descriptively. Results: In total, 3794 respondents were included in the analysis. Many (33.3% to 68.3%) reported being aware about TTS and its association with the vaccines from AstraZeneca and Janssen, though most were not familiar with the exact symptoms. Changes in willingness to be vaccinated with COVID-19 and other vaccines varied by country. The largest change in the willingness to be vaccinated with AstraZeneca and Janssen vaccines was in Denmark (61.2%), while the largest change in the willingness to be vaccinated with other COVID-19 vaccines was in Slovenia (30.4%).Conclusion: Information about TTS seemed to be considered by the public in the European countries resulting in changed willingness to be vaccinated with the COVID-19 vaccines from AstraZeneca and Janssen. Willingness to be vaccinated against other COVID-19 vaccines and vaccines in general seemed to be determined by the approaches of the national health authorities to react to and communicate about the COVID-19 vaccination risks. Further investigation of risk communication strategies is warranted.
AB - Objective: In 2021, thrombocytopenia syndrome (TTS) was confirmed by the European Medicines Agency (EMA) as a rare side effect of the COVID-19 adenovirus vector vaccines from AstraZeneca or Janssen. This study aimed to describe the public’s knowledge of TTS and how it affected the willingness to be vaccinated with COVID-19 and other vaccines.Methods: In 2022, a multi-country cross-sectional online survey was conducted in Denmark, Greece, Latvia, Netherlands, Portugal and Slovenia. The minimum target of participants to be recruited was linked to the country’s population. The results were analysed descriptively. Results: In total, 3794 respondents were included in the analysis. Many (33.3% to 68.3%) reported being aware about TTS and its association with the vaccines from AstraZeneca and Janssen, though most were not familiar with the exact symptoms. Changes in willingness to be vaccinated with COVID-19 and other vaccines varied by country. The largest change in the willingness to be vaccinated with AstraZeneca and Janssen vaccines was in Denmark (61.2%), while the largest change in the willingness to be vaccinated with other COVID-19 vaccines was in Slovenia (30.4%).Conclusion: Information about TTS seemed to be considered by the public in the European countries resulting in changed willingness to be vaccinated with the COVID-19 vaccines from AstraZeneca and Janssen. Willingness to be vaccinated against other COVID-19 vaccines and vaccines in general seemed to be determined by the approaches of the national health authorities to react to and communicate about the COVID-19 vaccination risks. Further investigation of risk communication strategies is warranted.
M3 - Poster
Y2 - 27 June 2023 through 30 June 2023
ER -
ID: 358434073